Biofrontera Inc.
Ameluz
mild to moderate actinic keratoses (AKs)
Resolved
148days ago
Phase 3 readout · Feb 9, 2026
What's at stake
Phase 3 trial results for Ameluz in mild to moderate actinic keratoses (AKs) are due Feb 9, 2026. A clean hit validates the program; a miss can gap the stock down hard.
Primary source
· SEC 8-K
verified 13h ago
“Biofrontera Announces Positive Results in Phase 3 Study of Ameluz PDT for Actinic Keratoses on the Extremities, Neck, and Trunk, Meeting Primary Endpoint”